| Line 1: |
Line 1: |
| − | Welcome! | + | Welcome! |
| | | | |
| − | *For assignments, please see the "Author" column below. If no name is present, volunteer to create content!
| |
| − | *We will be creating content for all entities with genetic findings in the current WHO Classification of Tumours books. '''<u>If there is an entity not yet listed below that you would like to author in any WHO book, we would be happy to create a page for you now</u>'''.
| |
| − | *To volunteer, please '''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' with your page of interest.
| |
| − | *'''<u>NOTE: A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated by late-2023; we're working on a plan to align the related CCGA content to the new structure.</u>'''
| |
| | | | |
| − | __TOC__
| + | We are creating content for all diseases with genetic findings in the current WHO Classification of Tumours books. Please join the effort! |
| | | | |
| − | ==WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content==
| |
| − | {| class="wikitable"
| |
| − | |-
| |
| − | !'''Disease'''!!'''Page Type'''!!'''Author'''
| |
| − | !'''Date Assigned to Author'''
| |
| − | !'''Target Completion Date'''
| |
| − | !'''Author Content (Pending or Complete)'''
| |
| − | !'''Date Completed by Author'''!!'''Associate Editor'''
| |
| − | !'''Date of Last Editor Review'''
| |
| − | !'''Notes'''
| |
| − | |-
| |
| − | |'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |Fabiola Quintero-Rivera (FQR)
| |
| − | |Date page was created
| |
| − | |
| |
| − | |-
| |
| − | | Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive||Disease
| |
| − | |Mark Evans (trainee)+Jack Reid (trainee)+Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |Date page was created
| |
| − | |
| |
| − | |-
| |
| − | | Chronic Neutrophilic Leukemia (CNL)||Disease
| |
| − | |Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |Date page was created
| |
| − | |
| |
| − | |-
| |
| − | | Polycythaemia Vera (PV)||Disease
| |
| − | |Gokce A. Toruner
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Primary Myelofibrosis (PMF)||Disease
| |
| − | |T. Niroshi Senaratne
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |8/4/2020 before submission
| |
| − | |
| |
| − | |-
| |
| − | | Essential Thrombocythaemia (ET)||Disease
| |
| − | |Rebecca Smith
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease
| |
| − | |Chelsea D. Kramish (trainee), Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |complete/pending faculty review
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease
| |
| − | |Thomas Lee
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Mastocytosis'''''||'''''Overview'''''||Shashi Shetty, Ph.D.
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | | ||FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Cutaneous Mastocytosis||Disease
| |
| − | |Thuy Phung + Shuo-Shawn Liu (trainee)
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Systemic Mastocytosis||Disease
| |
| − | |Shashi Shetty
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mast Cell Sarcoma||Disease
| |
| − | |Thuy Phung +Jordan Lowery (trainee)
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''||Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement||Disease||Jay Alden (trainee) +Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement||Disease||Christopher Sullivan (trainee) + Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement||Disease||Yanna Ding
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease||Jessica Snider (trainee) + Daynna J.Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Myeloid/Lymphoid Neoplasms with ETV6-JAK2
| |
| − | |Disease
| |
| − | |Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |Myeloid/Lymphoid Neoplasms with BCR-JAK2
| |
| − | |Disease
| |
| − | |Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |'''''Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)'''''||'''''Overview'''''||Linsheng Zhang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Chronic Myelomonocytic Leukemia (CMML)||Disease||Linsheng Zhang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease||Linsheng Zhang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Juvenile Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo
| |
| − | |
| |
| − | |9/1/20
| |
| − | |PENDING importing content and reference formatting
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |FQR has emailed SR several times, last 4/20/22
| |
| − | |-
| |
| − | | Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |Date page was created
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease||Ruth MacKinnon
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Jack Reid (trainee)+Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |4/21/22
| |
| − | |pending
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek
| |
| − | |
| |
| − | |9/1/20
| |
| − | |PENDING
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |9/1/20
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS) with Isolated del(5q)||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myelodysplastic Syndrome (MDS), Unclassifiable||Disease||Xiaolin Hu(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |
| |
| − | |complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Refractory Cytopenia of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek
| |
| − | |
| |
| − | |9/1/20
| |
| − | |Complete
| |
| − | |
| |
| − | |FQR
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Myelodysplastic Neoplasm with Biallelic TP53 Inactivation
| |
| − | |Disease
| |
| − | |Eric McGinnis
| |
| − | |
| |
| − | |5/4/23
| |
| − | |PENDING
| |
| − | | ||FQR
| |
| − | |
| |
| − | |'''Page New in 5th Edition of Book'''. 2021 template added.
| |
| − | |-
| |
| − | |'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''||Daynna Wolff+Daniel Butler (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |Jennelle Hodge (JH)/ Malini Sathanoori (MS)
| |
| − | |04/26/2021 -MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | |'''''Myeloid Neoplasms with Germline Predisposition'''''||'''''Overview'''''||Ying Zou
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukaemia with Germline CEBPA Mutation||Disease||Daynna Wolff+Matthew Kilpatrick (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |''<s>PENDING</s> Complete - awaiting clarification''
| |
| − | | ||JH / MS
| |
| − | |04/26/2021 -MS (re-review)
| |
| − | |Review completed, awaiting some clarification from JH - 07/04/2022
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline DDX41 Mutation||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline RUNX1 Mutation||Disease||Malini Sathanoori
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |02/03/2021||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline ANKRD26 Mutation||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/02/2021-MS
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline ETV6 Mutation||Disease||Ying Zou
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/02/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Neoplasms with Germline GATA2 Mutation||Disease||Daynna Wolff+ Alexandria Avery (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |04/26/2021 -MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | |'''''Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities'''''||'''''Overview'''''||Daynna Wolff+ Dan Wang (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease||Christine Bryke
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |04/26/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease||Christine Bryke
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Promyelocytic Leukemia (APL) with PML-RARA||Disease||Shashi Shetty
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease||Shashi Shetty
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |03/01/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease||Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |02/24/2021-MS (re-review)
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease||Gordana Raca
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Need permission for figure? Update WHO?
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease||Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with BCR-ABL1||Disease||Kay Weng Choy + Greg
| |
| − | Corboy (Monash Health)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Mutated NPM1||Disease||Xinjie Xu
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Add WHO reference
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg Corboy (Monash Health)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Mutated RUNX1||Disease||Daynna Wolff+Iris Martin (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Therapy-Related Myeloid Neoplasms||Disease||Shashi Shetty + Shawn A. Silver (resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Check reference format
| |
| − | |-
| |
| − | |''Acute Myeloid Leukemia (AML), Not Otherwise Specified''||'''''Overview'''''||Anwar Iqbal
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Minimal Differentiation||Disease||Fabiola Quintero-Rivera and Celeste Eno (fellow)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) without Maturation||Disease||Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myeloid Leukemia (AML) with Maturation||Disease||Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Myelomonocytic Leukemia||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Monoblastic and Monocytic Leukemia||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Pure Erythroid Leukemia||Disease||Ash Yenamandra
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Megakaryoblastic Leukemia (AMKL)||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Basophilic Leukemia||Disease||Ash Yenamandra
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Panmyelosis with Myelofibrosis||Disease||Ying Zou and Jialing Huang (MGP fellow)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Myeloid Sarcoma||Disease||Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Myeloid Proliferations Associated with Down Syndrome'''''||'''''Overview'''''||Patty Greipp
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Need permission for figure?
| |
| − | |-
| |
| − | | Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome||Disease||Linda Cooley
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Myeloid Leukemia Associated with Down Syndrome||Disease||Linda Cooley
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Blastic Plasmacytoid Dendritic Cell Neoplasm||Disease||Daynna Wolff+Hao Liu (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Acute Leukemias of Ambiguous Lineage'''''||'''''Overview'''''||Hui Chen/ Jennelle Hodge
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Undifferentiated Leukemia||Disease||Shashi Shetty + Amelia Nakanishi (resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |Check reference format
| |
| − | |-
| |
| − | | Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease||Tracy Tucker
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged||Disease||Tracy Tucker
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified||Disease||Shashi Shetty + Priyatharsini Nirmalanantham (resident)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types||Disease||Daynna Wolff+ Elicia Goodale (resident)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Acute Leukemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease||Daynna Wolff+Madison Hannay or Elicia Goodale (residents)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||JH / MS
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Acute Myeloid Leukemia (AML) with Mutated FLT3
| |
| − | |Disease
| |
| − | |Kay Weng Choy + Greg Corboy (Monash Health)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |JH / MS
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |Acute Myeloid Leukemia (AML) with NUP214-ABL1
| |
| − | |Disease
| |
| − | |Daynna Wolff+Jessica Snider (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |JH / MS
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | |Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6
| |
| − | |Disease
| |
| − | |Daynna Wolff+ Paige Woodham (Path Resident)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |JH / MS
| |
| − | |
| |
| − | |NON-WHO ENTITY
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||Holli Drendel (HD)
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | |'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged||Disease||Yassmine Akkari+Nicolas Millan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy||Disease||Ashwini Yenamandra +
| |
| | | | |
| − | Lisa Smith + Yassmine Akkari
| + | To volunteer: |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like||Disease||Mark G. Evans + Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma with iAMP21||Disease||Holli Drendel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease||Holli Drendel
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
| |
| − | |Disease
| |
| − | |Diana Rush
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |HD
| |
| − | |
| |
| − | |YA (prior AE); NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
| |
| − | |Disease
| |
| − | |Celeste Eno
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |HD
| |
| − | |
| |
| − | |YA (prior AE); NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
| |
| − | |Disease
| |
| − | |Marilena Melas
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |HD
| |
| − | |
| |
| − | |YA (prior AE); NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
| |
| − | |Disease
| |
| − | |Chenkai Ma
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |HD
| |
| − | |
| |
| − | |YA (prior AE); NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
| |
| − | |Disease
| |
| − | |Celeste Eno
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |HD
| |
| − | |
| |
| − | |YA (prior AE); NON-WHO ENTITY
| |
| − | |-
| |
| − | |B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
| |
| − | |Disease
| |
| − | |Alaa Koleilat
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |HD
| |
| − | |
| |
| − | |YA (prior AE); NON-WHO ENTITY
| |
| − | |-
| |
| − | |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE)
| |
| − | |-
| |
| − | |Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE); 2021 template added
| |
| − | |-
| |
| − | |NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||HD
| |
| − | |
| |
| − | |YA (prior AE); 2021 template added
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||Shivani Golem (SG)
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Jaime Nagy, PhD/
| |
| | | | |
| − | Renee Eigsti, MD
| + | #Select a link in the table to your book(s) of interest to view specific authorship opportunities. Additional books are in the process of being added. |
| − | |
| + | #'''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' with your disease page of interest. You will be connected with an Associate Editor to help guide you through the process. |
| − | |
| + | #Complete the brief '''[https://mms.cancergenomics.org/members/form.php?orgcode=CGC&fid=3830649 <u>Volunteer Form</u>]''' to receive your log-in credentials. Information on [[Description of CCGA Roles|<u>Authorship and Other Roles</u>]] with the CCGA is available. |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE); NOTE TO BAILEY: author updating page on staging server with conversion to new template (small amount of content on older template with 4th edition content - need to convert to new template and update to 5th edition content). Then transfer to production server when ready.
| |
| − | |-
| |
| − | | Monoclonal B-cell Lymphocytosis||Disease||Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
| |
| − | |12/19/2022
| |
| − | |1/19/2023
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE), 2021 template added
| |
| − | |-
| |
| − | |B-cell Prolymphocytic Leukemia||Disease||NOT NEEDED. DO NOT ASSIGN
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |SP (prior AE); 2021 template added; No longer an entity
| |
| − | |-
| |
| − | |Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Hairy Cell Leukemia||Disease||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Splenic Diffuse Red Pulp Small B-cell Lymphoma||Disease||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Hairy Cell Leukemia Variant||Disease||Snehal Patel
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Lymphoplasmacytic Lymphoma||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SG
| |
| − | |4/12/2023 by FQR
| |
| − | |SP (prior AE); 2021 template added
| |
| − | |-
| |
| − | | Waldenstrom Macroglobulinemia||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SG
| |
| − | |4/12/2023 by FQR
| |
| − | |SP (prior AE); 2021 template added
| |
| − | |-
| |
| − | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |'''''Heavy Chain Diseases'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Mu Heavy Chain Disease||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Gamma Heavy Chain Disease||Disease||Manisha Sutariya
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |5/26/2021||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Alpha Heavy Chain Disease||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Non-IgM Monoclonal Gammopathy of Undetermined Significance||Disease||Zhenya Tang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Plasmacytoma||Disease||Zhenya Tang
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |09/10/2022||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Primary Amyloidosis||Disease||Heather E. Williams, PhD
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Light Chain and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |10/15/2022||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
| |
| − | |8/31/2021
| |
| − | |9/15/2021
| |
| − | |PENDING
| |
| − | | ||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | TEMPI Syndrome||Disease||Sohini Anand, MBBS
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |SG
| |
| − | |4/12/23 by FQR
| |
| − | |SP (prior AE); 2021 template added
| |
| − | |-
| |
| − | |Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |5/28/2021||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |11/11/2020
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Follicular Lymphoma||Disease||Updating by Rachel Burnside; Ruthann Pfau
| |
| − | |7/28/2024
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE); has prior content in old template but same name in 5th edition - Rachel working on this outside of production site with new template to replace production site page later)
| |
| − | |-
| |
| − | | Testicular Follicular Lymphoma|| ||NOT NEEDED. DO NOT ASSIGN.
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |TO BE DELETED - NOT IN 5th EDITION
| |
| − | |-
| |
| − | | In Situ Follicular Neoplasia||Disease||Rachel Burnside
| |
| − | |7/28/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE); 2021 template added (no prior content; name to 5th edition version of In Situ Follicular B-cell Neoplasm will be changed later but Rachel working on 5th edition content in this production site)
| |
| − | |-
| |
| − | | Duodenal-Type Follicular Lymphoma||Disease||Rachel Burnside
| |
| − | |7/28/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE); 2021 template added (name same in 5th edition version and no prior content; Rachel working on 5th edition content in this production site)
| |
| − | |-
| |
| − | |Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/16/2020
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid
| |
| − | |
| |
| − | |9/30/20
| |
| − | |Complete
| |
| − | |5/26/2021||SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |09/10/2022
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Mantle Cell Lymphoma||Disease||Mahsa Khanlari
| |
| − | |
| |
| − | |8/15/20
| |
| − | |PENDING
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Leukemic Non-Nodal Mantle Cell Lymphoma||Disease||Tsigab Hagos (trainee)/Shashirekha.Shetty
| |
| − | |12/19/2022
| |
| − | |1/19/2022
| |
| − | |Pending
| |
| − | |
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | In Situ Mantle Cell Neoplasia||Disease||Rina Kansal, MD
| |
| − | |6/12/22
| |
| − | |
| |
| − | |Complete
| |
| − | |7/26/2022
| |
| − | |SG
| |
| − | |
| |
| − | |SP (prior AE); 2021 template added
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |Greg Corboy (GC)
| |
| − | |
| |
| − | |Requested to update 14022022
| |
| − | |-
| |
| − | |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||Laveniya Satgunaseelan
| |
| − | |26/10/2021
| |
| − | |26/1/2022
| |
| − | |Complete
| |
| − | |03/28/22||GC
| |
| − | |03/28/22
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |EBV-Positive Mucocutaneous Ulcer||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Fibrin-Associated Diffuse Large B-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Lymphomatoid Granulomatosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||Mary Haddadin
| |
| − | |9/5/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Intravascular Large B-cell Lymphoma||Disease||Kate Berry, Greg Corboy
| |
| − | |25/01/2022
| |
| − | |25/4/2022
| |
| − | |Complete
| |
| − | |9/1/22||GC
| |
| − | |9/1/22
| |
| − | |Emailed 28/3/2022 for progress update
| |
| − | |-
| |
| − | |ALK-Positive Large B-cell Lymphoma||Disease||Nakasaki Manando (fellow), Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
| |
| − | |-
| |
| − | |Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | | ||GC
| |
| − | |28/03/2022
| |
| − | |
| |
| − | |-
| |
| − | |Primary Effusion Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Multicentric Castleman Disease||Disease||Sudha Arumugam
| |
| − | |10/26/2021
| |
| − | |1/26/2022
| |
| − | |Complete
| |
| − | |24/01/2022||GC
| |
| − | |24/01/2022
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Xiao Zhou, MD, PhD, Siparadigm
| |
| − | |10/26/2021
| |
| − | |1/26/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |Emailed 28/3/2022 for progress update
| |
| − | |-
| |
| − | | HHV8-Positive Germinotropic Lymphoproliferative Disorder||Disease||Xiao Zhou, MD, PhD, Siparadigm
| |
| − | |10/26/2021
| |
| − | |1/26/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |Emailed 28/3/2022 for progress update
| |
| − | |-
| |
| − | |Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
| |
| − | |3/11/21
| |
| − | |06/28/2021
| |
| − | |Complete
| |
| − | |28/06/2021||GC
| |
| − | |28/06/2021
| |
| − | |
| |
| − | |-
| |
| − | |Burkitt-Like Lymphoma with 11q Aberration||Disease||Lauren Shealy (trainee), Daynna Wolff
| |
| − | |10/13/21
| |
| − | |01/13/2022
| |
| − | |Complete
| |
| − | |27/01/2022
| |
| − | |GC
| |
| − | |27/01/2021
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||Kate Berry, Greg Corboy
| |
| − | |30/05/21
| |
| − | |30/08/21
| |
| − | |Complete
| |
| − | |24/02/2022||GC
| |
| − | |24/02/2022
| |
| − | |
| |
| − | |-
| |
| − | | High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Aiko Otsubo, Holli Drendel
| |
| − | |7/30/21
| |
| − | |10/30/21
| |
| − | |Complete
| |
| − | |15/11/2021
| |
| − | |GC
| |
| − | |16/11/2021
| |
| − | |
| |
| − | |-
| |
| − | |B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||Sumi Kitahara (SK)
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |T-cell Prolymphocytic Leukemia||Disease||Michelle Don
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |11/21/2021||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Severe Mosquito Bite Allergy||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG
| |
| − | |
| |
| − | |
| |
| − | |?PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |'''''Intestinal T-cell Lymphoma'''''||'''''Overview'''''||Sumire Kitahara, Derick Okwan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |9/26/2022
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Enteropathy-Associated T-cell Lymphoma||Disease||Sumire Kitahara, Derick Okwan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |1/21/2021
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Monomorphic Epitheliotropic Intestinal T-cell Lymphoma||Disease||Sumire Kitahara
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sumire Kitahara, Derick Okwan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |9/26/2022
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract||Disease||Sumire Kitahara, Derick Okwan (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Hepatosplenic T-cell Lymphoma||Disease||Michelle Don
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |1/21/2021
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Mycosis Fungoides||Disease||Daynna Wolff, Jane Scribner (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee), Tingting Barrett (trainee)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders'''''||'''''Overview'''''||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Lymphomatoid Papulosis||Disease||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Bo Hong
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE); 2021 template added
| |
| − | |-
| |
| − | |'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | Angioimmunoblastic T-cell Lymphoma||Disease||Updating by Rachel Burnside; Ruthann Pfau, Sara Akhavanfard (trainee)
| |
| − | |7/28/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE); (has prior content and name will change in 5th edition - Rachel working on this outside of production site to be replaced later by Nodal TFH Cell Lymphoma, Angioimmunoblastic-Type)
| |
| − | |-
| |
| − | | Follicular T-cell Lymphoma||Disease||Rachel Burnside
| |
| − | |7/28/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE); 2021 template added (name to 5th edition version of Nodal TFH Cell Lymphoma, Follicular-Type will be changed later but Rachel working on 5th edition content in this production site)
| |
| − | |-
| |
| − | | Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype||Disease||Hans Hamnvåg
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Anaplastic Large Cell Lymphoma, ALK-Positive||Disease||Sumire Kitahara / Miguel Gonzalez (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Completed
| |
| − | |09/23/2022
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Anaplastic Large Cell Lymphoma, ALK-Negative||Disease||Sumire Kitahara / Miguel Gonzalez (trainee)
| |
| − | |
| |
| − | |
| |
| − | |Completed
| |
| − | |09/23/2022
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | |Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||Sumire Kitahara
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |SK
| |
| − | |
| |
| − | |SP (prior AE)
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Hodgkin Lymphomas'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||Greg Corboy (GC)
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||Thomas Harrington (resident) + Daynna Wolff
| |
| − | |06/22/2022
| |
| − | |09/22/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added, Daynna organising
| |
| − | |-
| |
| − | |'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Nodular Sclerosis Classic Hodgkin Lymphoma||Disease||Xiaolin (Lynn) Hu
| |
| − | |
| |
| − | |
| |
| − | |Completed
| |
| − | |03/21/22||GC
| |
| − | |03/21/22
| |
| − | |Edits sent 14022022
| |
| − | |-
| |
| − | | Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | Mixed Cellularity Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | | Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Lymphomas Associated with HIV Infection||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
| |
| − | |11/2/21
| |
| − | |02/02/22
| |
| − | |Completed
| |
| − | |03/21/22
| |
| − | |GC
| |
| − | |03/21/22
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Non-Destructive Post-Transplant Lymphoproliferative Disorders||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Polymorphic Post-Transplant Lymphoproliferative Disorders||Disease||Ania Shestakova (trainee) + Fabiola Quintero-Rivera
| |
| − | |
| |
| − | |
| |
| − | |completed
| |
| − | |april 2022
| |
| − | |GC
| |
| − | |26/4/2022
| |
| − | |
| |
| − | |-
| |
| − | |''''' Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Monomorphic B-cell PTLD||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Monomorphic T/NK-cell PTLD||Disease||NOT NEEDED. DO NOT ASSIGN.
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Histiocytic Sarcoma||Disease||Marie-France Gagnon, MD, Mayo Clinic (LGG fellow trainee), Xinjie Xu, PhD FACMG, Mayo Clinic
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |10/01/2021
| |
| − | |GC
| |
| − | |10/01/2021
| |
| − | |Xinjie Xu
| |
| − | |-
| |
| − | |'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Langerhans Cell Histiocytosis||Disease||Malaika Perchard, Greg Corboy
| |
| − | |02/01/2022
| |
| − | |05/01/2022
| |
| − | |Complete
| |
| − | |04/28/2022||GC
| |
| − | |5/19/2022
| |
| − | |
| |
| − | |-
| |
| − | | Langerhans Cell Sarcoma||Disease||Malaika Perchard, Greg Corboy
| |
| − | |02/01/2022
| |
| − | |05/01/2022
| |
| − | |Complete
| |
| − | |04/28/2022||GC
| |
| − | |5/19/2022
| |
| − | |
| |
| − | |-
| |
| − | |Indeterminate Dendritic Cell Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Interdigitating Dendritic Cell Sarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Follicular Dendritic Cell Sarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Fibroblastic Reticular Cell Tumor||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Disseminated Juvenile Xanthogranuloma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||GC
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Erdheim-Chester Disease||Disease||Prashant Deshpande
| |
| − | |02/02/2022
| |
| − | |05/02/2022
| |
| − | |PENDING
| |
| − | | ||GC
| |
| − | |
| |
| − | |emailed 28/3/2022 to get update
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | | || ||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | ||
| |
| − | |
| |
| − | |
| |
| − | |}<br />
| |
| | | | |
| − | ==WHO Classification of Soft Tissue and Bone Tumours (5th Edition) Content==
| |
| − | {| class="wikitable"
| |
| − | |-
| |
| − | !'''Disease'''!!'''Page Type'''!!'''Author'''
| |
| − | !'''Date Assigned to Author'''
| |
| − | !'''Target Completion Date'''
| |
| − | !'''Author Content (Pending or Complete)'''
| |
| − | !'''Date Completed by Author'''!!'''Associate Editor'''
| |
| − | !'''Date of Last Editor Review'''
| |
| − | !'''Notes'''
| |
| − | |-
| |
| − | |NTRK-Rearranged Spindle Cell Neoplasm||Disease||James Solomon, MD, PhD
| |
| − | |2/20/2022
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |Alanna Church
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Ewing Sarcoma
| |
| − | |Disease
| |
| − | |Sadeem Qdaisat
| |
| − | |10/1/23
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |Working with Eric McGinnis
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |}<br />
| |
| | | | |
| − | ==WHO Classification of Tumours of the Central Nervous System (5th Edition) Content==
| |
| | {| class="wikitable" | | {| class="wikitable" |
| | + | |+BOOKS WITH CONTENT IN PROGRESS |
| | + | !Book Name |
| | + | !Book Edition |
| | + | !Book Acronym |
| | |- | | |- |
| − | !'''Disease'''!!'''Page Type'''!!'''Author'''
| + | |[[HAEM5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues]] |
| − | !'''Date Assigned to Author'''
| + | |5th |
| − | !'''Target Completion Date'''
| + | |HAEM5 |
| − | !'''Author Content (Pending or Complete)'''
| |
| − | !'''Date Completed by Author'''!!'''Associate Editor'''
| |
| − | !'''Date of Last Editor Review'''
| |
| − | !'''Notes'''
| |
| | |- | | |- |
| − | |Astrocystoma, IDH-Mutant | + | |[[CNS5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of the Central Nervous System]] |
| − | |Disease
| + | |5th |
| − | |Meenakshi Mehrotra
| + | |CNS5 |
| − | |6/25/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |Laveniya Satgunaseelan (LS) | |
| − | | | |
| − | |2021 template added | |
| | |- | | |- |
| − | |Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted||Disease||Riley Lochner (trainee), Shashi Shetty (mentor) | + | |[[GTS5:Volunteer Assignments and Opportunities|WHO Classification of Genetic Tumour Syndromes]] |
| − | |6/7/2022
| + | |5th |
| − | |
| + | |GTS5 |
| − | |COMPLETE
| |
| − | |
| |
| − | |LS
| |
| − | | | |
| − | |2021 template added | |
| | |- | | |- |
| − | |Glioblastoma, IDH-Wildtype||Disease||Meenakshi Mehrotra | + | |[[BRST5:Volunteer Assignments and Opportunities|WHO Classification of Tumours of the Breast]] |
| − | |
| + | |5th |
| − | |
| + | |BRST5 |
| − | |PENDING
| |
| − | |
| |
| − | |LS
| |
| − | | | |
| − | |Moved from "Glioblasoma, IDH-wildtype" to new page; 2021 template added | |
| | |- | | |- |
| − | |Diffuse Astrocytoma, MYB- or MYBL1-Altered||Disease||Scott Smith | + | |[[STBT5:Volunteer Assignments and Opportunities|WHO Classification of Soft Tissue and Bone Tumours]] |
| − | |6/27/2023
| + | |5th |
| − | |
| + | |STBT5 |
| − | |PENDING
| + | |} |
| − | |
| + | |
| − | |LS
| + | |
| − | |
| |
| − | |2021 template added (page created 6/27/23)
| |
| − | |-
| |
| − | |Angiocentric Glioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Polymorphous Low-Grade Neuroepithelial Tumour of the Young||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Low-Grade Glioma, MAPK Pathway-Altered||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Midline Glioma, H3 K27-Altered||Disease||Laveniya Satgunaseelan (Linda Cooley - previous version)
| |
| − | |
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |LS
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Diffuse Hemispheric Glioma, H3 G34-Mutant||Disease||Xiaolin (Lynn) Hu
| |
| − | |2/21/2022
| |
| − | |
| |
| − | |COMPLETE
| |
| − | |
| |
| − | |LS
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype||Disease||Madina Sukhanova
| |
| − | |10/28/2022
| |
| − | |
| |
| − | |COMPLETE
| |
| − | |
| |
| − | |LS
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Infant-Type Hemispheric Glioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Pilocytic Astrocytoma||Disease||Jeremy Pulvers
| |
| − | |9/13/2022<br />
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |LS
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |High-Grade Astrocytoma with Piloid Features||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Pleomorphic Xanthoastrocytoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |LS
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Subependymal Giant Cell Astrocytoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Chordoid Glioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Astroblastoma, MN1-Altered||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Ganglioglioma||Disease||Leila Moayed-Aloei
| |
| − | |6/30/2022
| |
| − | |
| |
| − | |COMPLETE
| |
| − | |
| |
| − | |LS
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Gangliocytoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Desmoplastic Infantile Ganglioglioma/Desmoplastic Infantile Astrocytoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Dysembryoplastic Neuroepithelial Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Glioneuronal Tumour with Oligodendroglioma-Like Features and Nuclear Clusters||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Papillary Glioneuronal Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Rosette-Forming Glioneuronal Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Myxoid Glioneuronal Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Lptomeningeal Glioneuronal Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Multinodular and Vacuolating Neuronal Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Dysplastic Cerebellar Gangliocytoma (Lhermitte-Duclos Disease)||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Central Neurocytoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Extraventricular Neurocytoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Cerebellar Liponeurocytoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Supratentorial Ependymoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Supratentorial Ependymoma, ZFTA Fusion-Positive||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Supratentorial Ependymoma, YAP1 Fusion-Positive||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Posterior Fossa Ependymoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Posterior Fossa Group A (PFA) Ependymoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Posterior Fossa Group B (PFB) Ependymoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Spinal Ependymoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Spinal Ependymoma, MYCN-Amplified||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Myxopapillary Ependymoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Subependymoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Choroid Plexus Papilloma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Atypical Choroid Plexus Papilloma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Choroid Plexus Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Medulloblastoma, WNT-Activated||Disease||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
| |
| − | |9/20/21
| |
| − | |
| |
| − | |COMPLETE
| |
| − | |
| |
| − | |Holli Drendel (interim)/Laveniya Satgunaseelan (LS)
| |
| − | |9/22/2022
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Medulloblastoma, SHH-Activated and TP53-Wildtype||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Medulloblastoma, SHH-Activated and TP53-Mutant||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Medulloblastoma, Non-WNT/Non-SHH||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Medulloblastoma, Histologically Defined||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Atypical Teratoid/Rhabdoid Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Cribriform Neuroepithelial Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Embryonal Tumour with Multilayered Rosettes||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CNS Neuroblastoma, FOXR2-Activated||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CNS Tumour with BCOR Internal Tandem Duplication||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CNS Embryonal Tumour NEC/NOS||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Pineocytoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Pineal Parenchymal Tumour of Intermediate Differentiation||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Pineoblastoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Papillary Tumour of the Pineal Region||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Desmoplastic Myxoid Tumour of the Pineal Region, SMARCB1-Mutant||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Schwannoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Neurofibroma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Perineurioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Hybrid Nerve Sheath Tumours||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Malignant Melanotic Nerve Sheath Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Malignant Peripheral Nerve Sheath Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Cauda Equina Neuroendocrine Tumour (Previously Paraganglioma)||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Meningioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Solitary Fibrous Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Haemangiomas and Vascular Malformations||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Haemangioblastoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Rhabdomyosarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Intracranial Mesenchymal Tumour, FET::CREB Fusion-Positive||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CIC-Rearranged Sarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Primary Intracranial Sarcoma, DICER1-Mutant||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Ewing Sarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Mesenchymal Chondrosarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Chondrosarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Chordoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Meningeal Melanocytic Neoplasms: Melanocytosis and Melanomatosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Circumscribed Meningeal Melanocytic Neoplasms: Melanocytoma and Melanoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Immunodeficiency-Associated CNS Lymphomas||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Lymphomatoid Granulomatosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Intravascular Large B-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MALT Lymphoma of the Dura||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Other Low-Grade B-cell Lymphomas of the CNS||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Anaplastic Large Cell Lymphoma (ALK+/ALK−)||Disease||Jennie Thurston
| |
| − | |7/2/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |MS
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |T-cell and NK/T-cell Lymphomas||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Erdheim-Chester Disease||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Rosai-Dorfman Disease||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Juvenile Xanthogranuloma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Langerhans Cell Histiocytosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Histiocytic Sarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Germ Cell Tumours of the CNS||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Adamantinomatous Craniopharyngioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Papillary Craniopharyngioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Pituicytoma, Granular Cell Tumour of the Sellar Region, and Spindle Cell Oncocytoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Pituitary Adenoma/Pituitary Neuroendocrine Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Pituitary Blastoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Metastases to the Brain and Spinal Cord Parenchyma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Metastases to the Meninges||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Neurofibromatosis Type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
| |
| − | |-
| |
| − | |Neurofibromatosis Type 2||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Schwannomatosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Von Hippel-Lindau Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Tuberous Sclerosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Li-Fraumeni Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Cowden Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Constitutional Mismatch Repair Deficiency Syndrome||Disease||Jennie Thurston
| |
| − | |7/2/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |LS
| |
| − | |
| |
| − | |NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
| |
| − | |-
| |
| − | |Familial Adenomatous Polyposis 1||Disease||Jennifer Laffin
| |
| − | |8/22/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |LS/MS
| |
| − | |
| |
| − | |NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
| |
| − | |-
| |
| − | |Naevoid Basal Cell Carcinoma Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Rhabdoid Tumour Predisposition Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Carney Complex||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |DICER1 Syndrome||Disease||Jennie Thurston
| |
| − | |7/2/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |LS
| |
| − | |
| |
| − | |NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
| |
| − | |-
| |
| − | |Familial Paraganglioma Syndromes||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Melanoma-Astrocytoma Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Familial Retinoblastoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |BAP1 Tumour Predisposition Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Fanconi Anaemia||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ELP1-Medulloblastoma Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |}<br />
| |
| − | ==WHO Classification of Tumours of the Breast (5th Edition) Content==
| |
| − | {| class="wikitable"
| |
| − | |-
| |
| − | !'''Disease'''!!'''Page Type'''!!'''Author'''
| |
| − | !'''Date Assigned to Author'''
| |
| − | !'''Target Completion Date'''
| |
| − | !'''Author Content (Pending or Complete)'''
| |
| − | !'''Date Completed by Author'''!!'''Associate Editor'''
| |
| − | !'''Date of Last Editor Review'''
| |
| − | !'''Notes'''
| |
| − | |- |Usual ductal hyperplasia||Disease||
| |
| − | |Usual Ductal Hyperplasia
| |
| − | |Disease
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Columnar Cell Lesions, Including Flat Epithelial Atypia||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Atypical Ductal Hyperplasia||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Sclerosing Adenosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Apocrine Adenosis and Adenoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Microglandular Adenosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Radial Scar/Complex Sclerosing Lesion||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Tubular Adenoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Lactating Adenoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Ductal Adenoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Pleomorphic Adenoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Adenomyoepithelioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Malignant Adenomyoepithelioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Intraductal Papilloma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Papillary Ductal Carcinoma In Situ||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Encapsulated Papillary Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Solid Papillary Carcinoma (In Situ and Invasive)||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Invasive Papillary Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Atypical Lobular Hyperplasia||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Lobular Carcinoma In Situ||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Ductal Carcinoma In Situ||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Invasive Breast Carcinoma of No Special Type||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Microinvasive Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Invasive lobular Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Tubular Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Cribriform Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Mucinous Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Mucinous Cystadenocarcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Invasive Micropapillary Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Carcinoma with Apocrine Differentiation||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Metaplastic Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Acinic Cell Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Adenoid Cystic Carcinoma||Disease||Katherine Geiersbach and Jun Liao
| |
| − | |10/12/02022
| |
| − | |11/11/2023
| |
| − | |COMPLETE
| |
| − | |
| |
| − | |Hui Chen / Katherine Geiersbach
| |
| − | |12/6/2023
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Secretory Carcinoma||Disease||Hui Chen
| |
| − | |10/12/2022
| |
| − | |11/11/2023
| |
| − | |PENDING
| |
| − | |
| |
| − | |Katherine Geiersbach
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Mucoepidermoid Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Polymorphous Adenocarcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Tall Cell Carcinoma with Reversed Polarity||Disease||H. Evin Gulbahce
| |
| − | |8/11/2023
| |
| − | |10/11/2023
| |
| − | |COMPLETE
| |
| − | |
| |
| − | |Katherine Geiersbach
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Neuroendocrine Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Neuroendocrine Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Hamartoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Fibroadenoma||Disease||H. Evin Gulbahce / Patricija Zot
| |
| − | |8/11/2023
| |
| − | |11/11/2023
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Phyllodes Tumour||Disease||H. Evin Gulbahce / Patricija Zot / Emilie Lalonde / Katherine Geiersbach
| |
| − | |8/11/2023
| |
| − | |11/11/2023
| |
| − | |PENDING
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Syringomatous Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Nipple Adenoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Paget disease of the Breast||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Haemangioma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Angiomatosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Atypical Vascular Lesions||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Postradiation Angiosarcoma of the Breast||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Primary Angiosarcoma of the Breast||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Nodular Fasciitis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Myofibroblastoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Desmoid Fibromatosis||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Inflammatory Myofibroblastic Tumour||Disease||Yajuan Liu
| |
| − | |8/11/2023
| |
| − | |11/11/2023
| |
| − | |COMPLETE
| |
| − | |
| |
| − | |Katherine Geiersbach
| |
| − | |12/6/2023
| |
| − | |2021 template added
| |
| − | |-
| |
| − | |Schwannoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Neurofibroma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Granular Cell Tumour||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Leiomyoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Leiomyosarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Lipoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Angiolipoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Liposarcoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Pseudoangiomatous Stromal Hyperplasia||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Follicular Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Diffuse Large B-cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Burkitt Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Gynaecomastia||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Carcinoma In Situ||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Invasive Carcinoma||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Metastases to the Breast||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||Constance Albarracin / Katherine Geiersbach
| |
| − | |12/6/2023
| |
| − | |3/6/2024
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Cowden Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Ataxia-Telangiectasia||Disease||Evin Gulbahce / Katherine Geiersbach
| |
| − | |12/11/2023
| |
| − | |3/11/2024
| |
| − | |
| |
| − | |
| |
| − | |Katherine Geiersbach
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Li-Fraumeni Syndrome, TP53-Associated||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Li-Fraumeni Syndrome, CHEK2-Associated||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CDH1-Associated Breast Cancer||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| − | |-
| |
| − | |PALB2-Associated Cancers||Disease||Constance Albarracin / Katherine Geiersbach
| |
| − | |12/8/2023
| |
| − | |3/8/2024
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Peutz-Jeghers Syndrome||Disease||
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |Neurofibromatosis Type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
| |
| − | |-
| |
| − | |Polygenic Component of Breast Cancer Susceptibility
| |
| − | |Disease
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |}<br />
| |
| − | ==Genetic Tumour Syndromes (5th Edition) Content==
| |
| | {| class="wikitable" | | {| class="wikitable" |
| | + | |+BOOKS COMING SOON |
| | + | !Book Name |
| | + | !Book Edition |
| | + | !Book Acronym |
| | |- | | |- |
| − | !'''Disease'''!!'''Page Type'''!!'''Author'''
| + | |[[DIG5:Volunteer Assignments and Opportunities|WHO Classification of Digestive System Tumours]] |
| − | !'''Date Assigned to Author'''
| + | |5th |
| − | !'''Target Completion Date'''
| + | |DIG5 |
| − | !'''Author Content (Pending or Complete)'''
| |
| − | !'''Date Completed by Author'''!!'''Associate Editor'''
| |
| − | !'''Date of Last Editor Review'''
| |
| − | !'''Notes'''
| |
| − | |-
| |
| − | |Constitutional Mismatch Repair Deficiency (CMMRD) syndrome (MLH1, PMS2, MSH2, MSH6)||Disease||Jennie Thurston
| |
| − | |7/2/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |LS
| |
| − | |
| |
| − | |Named based on GTS5 book
| |
| − | |-
| |
| − | |DICER1-Related Tumour Predisposition Syndrome (DICER1)
| |
| − | |Disease
| |
| − | |Jennie Thurston
| |
| − | |7/2/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | | | |
| − | |LS | |
| − | |
| |
| − | |Named based on GTS5 book
| |
| − | |-
| |
| − | |Neurofibromatosis Type 1 (NF1)
| |
| − | |Disease
| |
| − | |Ngoni Faya (trainee) + Madina Sukhanova
| |
| − | |7/12/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |Madina Sukhanova (Madina S)
| |
| − | |
| |
| − | |Named based on GTS5 book
| |
| − | |-
| |
| − | |Familial Adenomatous Polyposis (APC)
| |
| − | |Disease
| |
| − | |Jennifer Laffin
| |
| − | |8/20/2023
| |
| − | |
| |
| − | |PENDING
| |
| − | |
| |
| − | |MS / LS
| |
| − | |
| |
| − | |Named based on GTS5 book
| |
| − | |-
| |
| − | |}<br />
| |
| − | | |
| − | ==Gene-Specific Pages (IN PROCESS OF AUTOMATING - HOLD ON VOLUNTEERING)==
| |
| − | {| class="wikitable sortable"
| |
| − | !'''Gene'''
| |
| − | !'''Author'''
| |
| − | !'''Date Assigned to Author'''
| |
| − | !'''Target Completion Date'''
| |
| − | !'''Author Content (Pending or Complete)'''
| |
| − | !'''Date Completed by Author'''
| |
| − | !'''Associate Editor'''
| |
| − | !'''Date of Last Editor Review'''
| |
| − | !'''Notes'''
| |
| − | |-
| |
| − | |BCR
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/10/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ABL1
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |4/16/19
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RUNX1
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |6/9/19
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RUNX1T1
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |5/23/19
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MYH11
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/6/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |FLT3
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |NPM1
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |TP53
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |DNMT3A
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CEBPA
| |
| − | |Gordana
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |IDH1
| |
| − | |Paul De Fazio
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |IDH2
| |
| − | |Paul De Fazio
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |PML
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |12/5/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RARA
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/3/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ETV6
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |6/9/19
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |KIT
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |10/1/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CBFB
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |8/2/18
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |GATA2
| |
| − | |Kay Weng Choy
| |
| − | |
| |
| − | |
| |
| − | |Complete
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |PTEN
| |
| − | |Beth Pitel
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MLTT3
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MECOM
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |FGFR1(FLT2)
| |
| − | |Brian Davis
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |KMT2A
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |DEK
| |
| − | |Wahab A. Khan
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |NUP214
| |
| − | |Wahab A. Khan
| |
| − | |
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RBM15
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MKL1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |DDX41
| |
| − | |Ying Zou
| |
| − | |8/7/20
| |
| − | |
| |
| − | |Pending
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ANKRD26
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CUX1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |TET2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |EZH2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |FOXP1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MYC
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |JAK2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |WT1
| |
| − | |DONE
| |
| − | |
| |
| − | |
| |
| − | |DONE
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CBL
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |NF1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |SUZ12
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ERG
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |EST2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RPS14
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |RB1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |MPL
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CHGA
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |CDH1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |SRSF2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |DNMT1
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |PRDX2
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |ASXL1
| |
| − | |DONE
| |
| − | |
| |
| − | |
| |
| − | |DONE
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |MN1 | + | |[[EYE5:Volunteer Assignments and Opportunities|WHO Classification of Eye and Orbit Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |EYE5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |SF3A1 | + | |[[SKIN5:Volunteer Assignments and Opportunities|WHO Classification of Skin Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |SKIN5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |EP300 | + | |[[HAN5:Volunteer Assignments and Opportunities|WHO Classification of Head and Neck Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |HAN5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |JARID2 | + | |[[ENDO5:Volunteer Assignments and Opportunities|WHO Classification of Endocrine and Neuroendocrine Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |ENDO5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |BRCA1 | + | |[[MALE5:Volunteer Assignments and Opportunities|WHO Classification of Urinary and Male Genital Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |MALE5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | |BRCA2 | + | |[[PEDS5:Volunteer Assignments and Opportunities|WHO Classification of Paediatric Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |PEDS5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | | | + | |[[THOR5:Volunteer Assignments and Opportunities|WHO Classification of Thoracic Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |THOR5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |- | | |- |
| − | | | + | |[[FEMA5:Volunteer Assignments and Opportunities|WHO Classification of Female Genital Tumours]] |
| − | |
| + | |5th |
| − | |
| + | |FEMA5 |
| − | |
| |
| − | |
| |
| − | |
| |
| − | | | |
| − | | | |
| − | | | |
| | |} | | |} |